Shares Soar as GH Research Unveils Promising Drug Trial

By Patricia Miller

Feb 04, 2025

2 min read

GH Research PLC's stock soared 89% after promising results for GH001, an innovative therapy for treatment-resistant depression. Explore the potential.

Digital Portrait of Visionary Mind isolated

What You Need To Know

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company, focuses on developing treatments for treatment-resistant depression. Following positive results from its Phase 2b clinical trial of GH001, an experimental psychedelic therapy, shares of the company soared, ending the day up 69.72%.

The trial successfully met its primary endpoint, demonstrating a significant reduction in the Montgomery-Åsberg Depression Rating Scale. Importantly, the therapy exhibited a favorable safety profile, with no serious adverse events reported during the trial.

In addition to its clinical achievements, GH Research announced a proposed public offering in the U.S. for $150 million in ordinary shares, which may include an option for underwriters to purchase up to an additional $22.5 million in shares.

Sign up for Investing Intel Newsletter

Get the latest news and updates from our team.

I agree to the privacy policy.

Why This Is Important for Retail Investors

  1. Significant stock price increase indicates strong market confidence in GH Research's prospects, potentially offering lucrative investment opportunities.

  2. Positive trial results for GH001 underscore the growing role of psychedelic therapies in treating mental health issues, opening avenues for future investments in innovative healthcare solutions.

  3. The announced public offering may provide funds for further research and development, enhancing the company's growth potential and long-term value.

  4. Retail investors can benefit from diversification opportunities by investing in related ETFs focused on biotechnology and mental health sectors.

Relevant ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some relevant ETFs include the following:

  • VanEck Vectors Biotech ETF

  • AdvisorShares Psychedelics ETF

  • iShares Nasdaq Biotechnology ETF

  • SPDR S&P Biotech ETF

  • First Trust NYSE Arca Biotechnology Index Fund

  • ARK Genomic Revolution ETF

  • Invesco S&P SmallCap Health Care ETF

Discover the World's Pharma Giants

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Initial Public Offering (IPO) Investing Stocks Healthcare

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.